(Q41332329)

29 September 2017

1 reference

title

Developments in antithrombotic therapy: state of the art anno 1996. (English)

1 reference

29 September 2017

H ten Cate

1

1 reference

29 September 2017

M T Nurmohamed

series ordinal

2

1 reference

29 September 2017

J W ten Cate

series ordinal

3

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 December 1996

1 reference

International Journal of Clinical Pharmacy

29 September 2017

published in

1 reference

29 September 2017

volume

18

1 reference

29 September 2017

issue

6

1 reference

29 September 2017

page(s)

195-203

1 reference

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

Large-dose infusions of heparinoid ORG 10172 in ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF00735960

Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans

21 January 2018

1 reference

12 December 2020

Structure of the hirugen and hirulog 1 complexes of alpha-thrombin

1 reference

12 December 2020

Selective and nonselective inhibition of thromboxane formation

1 reference

12 December 2020

A randomised, double-blind, placebo-controlled trial of dermatan sulphate for prevention of deep vein thrombosis in hip fracture

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

LY53857, a 5HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion

1 reference

12 December 2020

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

12 December 2020

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

12 December 2020

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

12 December 2020

Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor

1 reference

12 December 2020

Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement

1 reference

12 December 2020

Maintenance of Coronary Patency After Fibrinolysis With Tissue Factor Pathway Inhibitor

1 reference

12 December 2020

Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

1 reference

12 December 2020

Heparin-induced thrombocytopenia and thrombosis

1 reference

12 December 2020

Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis

1 reference

12 December 2020

Clinical studies with low-molecular-weight heparin(oid)s: an interim analysis

1 reference

12 December 2020

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

1 reference

12 December 2020

Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma

1 reference

12 December 2020

Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges

1 reference

12 December 2020

Novel antithrombotic approaches to coronary artery disease

1 reference

12 December 2020

ADP plays a key role in thrombogenesis in rats

1 reference

12 December 2020

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

12 December 2020

Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate

1 reference

12 December 2020

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

12 December 2020

Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa.

1 reference

12 December 2020

Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin

1 reference

12 December 2020

Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery.

1 reference

12 December 2020

Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin

1 reference

12 December 2020

SC-54684A: an orally active inhibitor of platelet aggregation

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

The development of hirudin as an antithrombotic drug

1 reference

12 December 2020

Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients.

1 reference

12 December 2020

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

12 December 2020

The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.

1 reference

12 December 2020

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

12 December 2020

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

12 December 2020

Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects

1 reference

12 December 2020

Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells

1 reference

12 December 2020

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock

1 reference

12 December 2020

The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate

1 reference

12 December 2020

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

12 December 2020

Ticlopidine hydrochloride use and threatened stroke.

1 reference

12 December 2020

Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates

1 reference

12 December 2020

Increased platelet deposition on atherosclerotic coronary arteries

1 reference

12 December 2020

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

12 December 2020

An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey

1 reference

12 December 2020

Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty

1 reference

12 December 2020

Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement

1 reference

12 December 2020

Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs

1 reference

12 December 2020

Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides

1 reference

12 December 2020

Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt

1 reference

12 December 2020

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

12 December 2020

Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty

1 reference

12 December 2020

Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees

1 reference

12 December 2020

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

12 December 2020

[Current viewpoints and hypotheses concerning in vivo blood coagulation]

1 reference

12 December 2020

Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216

1 reference

12 December 2020

Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models

1 reference

12 December 2020

The coagulation cascade: initiation, maintenance, and regulation

1 reference

12 December 2020

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

1 reference

12 December 2020

Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study

1 reference

12 December 2020

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

1 reference

12 December 2020

Dermatan sulphate: A safe approach to prevention of postoperative deep vein thrombosis

1 reference

12 December 2020

Low molecular weight heparin

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin

1 reference

12 December 2020

A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis

1 reference

12 December 2020

Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation

1 reference

12 December 2020

Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor

1 reference

12 December 2020

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

1 reference

12 December 2020

Low molecular weight heparin in prevention of perioperative thrombosis

1 reference

12 December 2020

Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist

1 reference

12 December 2020

Reduction in thrombus formation by PG-1 F(ab')2, an anti-guinea pig platelet glycoprotein Ib monoclonal antibody

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators

1 reference

12 December 2020

The haemorrhagic and antithrombotic effects of dermatan sulphate

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00735960

1 reference

29 September 2017

1 reference